Newsroom

PARIS--(BUSINESS WIRE)--  TotalEnergies and KKR, a leading global investment firm, today announced the signing of an agreement to add 700 MW to the 50/50 Joint-Venture (JV) they created in the U.S. in 2025, which currently holds 1.4 GW. The transaction covers a portfolio of three utility scale solar assets located in Texas and in Ohio which are expected to reach their commercial operation dates by the first quarter of 2027. The electricity produced by these assets is already sold to third parti...

PARIS--(BUSINESS WIRE)--TotalEnergies and KKR, a leading global investment firm, today announced the signing of an agreement to add 700 MW to the 50/50 Joint-Venture (JV) they created in the U.S. in 2025, which currently holds 1.4 GW. The transaction covers a portfolio of three utility scale solar assets located in Texas and in Ohio which are expected to reach their commercial operation dates by the first quarter of 2027. The electricity produced by these assets is already sold to third parties...

PARIS--(BUSINESS WIRE)--TotalEnergies et KKR, une société d’investissement mondiale de premier plan, ont annoncé aujourd’hui la signature d’un accord afin d’ajouter 700 MW à leur coentreprise (50/50), créée en 2025 aux États-Unis et qui détient actuellement 1,4 GW de capacités. La transaction porte sur un portefeuille de trois centrales solaires de grandes tailles situées au Texas et dans l’Ohio, dont la mise en service est attendue d’ici le 1er trimestre 2027. L’électricité produite par ces ac...

PARIS--(BUSINESS WIRE)--Regulatory News: Gecina (Paris:GFC): Gecina a signé deux nouveaux baux longs d’envergure sur ses actifs à Paris La Défense, le Bâtiment B et Adamas, tous deux adjacents à Shape (ex Tour T1), avec des durées fermes de plus de 11 ans (pour un total de 29 000 m²). Ces transactions portent l’occupation de ces deux immeubles à 100 % et confirment les fondamentaux solides de ce marché pour les meilleurs actifs. Gecina a signé, avec un leader international de l’énergie nucléair...

PARIS--(BUSINESS WIRE)--Regulatory News: Gecina (Paris:GFC): Gecina has signed two new major long-term leases in Paris La Défense for Building B and Adamas, both adjacent to T1/Shape, with firm terms of over 11 years (for a total of 29,000 sq.m). These transactions ensure full occupancy for both buildings and confirm this submarket’s solid fundamentals for the best assets. Gecina has signed an 11.5-year firm lease with an international leader in nuclear energy for 100% of Building B (21,000 sq....

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), today announces the completion of the acquisition of 100% of the share capital and voting rights of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"). Further to the closing of the cash consideration of the Acquisition which occurred in August1, the Company has now proceeded to...

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), société de biotechnologie pionnière dans le domaine des thérapies de précision de nouvelle génération à base d’ARN ciblés (« Valerio » ou la « Société »), annonce aujourd’hui la réalisation de l’Acquisition de 100 % du capital social et des droits de vote d’Etherna Immunotherapies NV (« Etherna ») (l’« Acquisition »). À la suite du règlement de la contrepartie en numéraire de l'Acquisition, qui a e...

WOIPPY, France--(BUSINESS WIRE)--Regulatory News: ABL Texcell Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6), a company specializing in molecular diagnostic solutions, healthcare software, and services supporting clinical research and biopharmaceutical development, today announces the acquisition of IntegraGen’s assets and business operations (www.integragen.com, Euronext Growth Paris: ALINT – ISIN: FR0010908723), pursuant to the ruling handed down by the Evry Commercial Court on Frida...

WOIPPY, France--(BUSINESS WIRE)--Regulatory News: ABL Texcell Diagnostics (Euronext Paris : ABLD – ISIN : FR001400AHX6), société spécialisée dans les solutions de diagnostic moléculaire, les logiciels de santé et les services associés à la recherche clinique et au développement biopharmaceutique, annonce la reprise des actifs et activités d’IntegraGen (www.integragen.com, Euronext Growth Paris ALINT – ISIN : FR0010908723), conformément au jugement rendu le vendredi 9 octobre 2026 par le Tribuna...

GALASHIELS, Scotland & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany, the findings represent one...